Photo via Toronto Star

XORTX Announces Planned FDA IND Submission for XRx-026 Gout Program Using XORLO™, Targeting USD$700M+ U.S. Gout Market Opportunity

Read the original at Toronto Star ↗
Cite

XORTX Announces Planned FDA IND Submission for XRx-026 Gout Program Using XORLO™, Targeting USD$700M+ U.S. Gout Market Opportunity. (2026, September 18). Toronto Star. https://www.thestar.com/globenewswire/xortx-announces-planned-fda-ind-submission-for-xrx-026-gout-program-using-xorlo-targeting-usd/article_efeec1ed-7a0b-5f47-8a61-aeaa8f362a01.html

Dated when The Aporia collected the article, usually within hours of publication. Check the original for its exact date and byline.

Toronto Star · collected 2026-09-18 · by GlobeNewswire, Inc.

Quick Summary

On September 18, 2026, XORTX Therapeutics Inc., a pharmaceutical company developing therapies for gout and kidney disease, announced plans to submit an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) by the end of 2026 for its drug candidate XRx-026. The submission aims to pave the way for a marketing approval application targeting the $700 million U.S. gout market, based on two-part clinical trials that will assess the pharmacokinetics and efficacy of XORLO™ oxypurinol formulation.
Written by AI on 2026-09-19, from this article's own text only (the story summary below draws on all the coverage).

AI analysis

Story summary

XORTX Therapeutics Inc., a pharmaceutical company based in Calgary, announced plans to submit an Investigational New Drug application (IND) to the U.S. Food and Drug Administration (FDA) for its XRx-026 gout program by the end of 2026. The company aims to develop XORLO™, a formulation of oxypurinol, as a new therapeutic option targeting the $700 million+ U.S. gout market. To secure FDA marketing approval, XORTX plans to conduct a two-part clinical study to assess the drug's pharmacokinetics and efficacy, followed by manufacturing enough commercial supply for its first year on the market. The company’s efforts include preparing for meetings with the FDA to navigate regulatory requirements effectively.

Written for “XORTX FDA Submission Gout Treatment” on 2026-10-31, grounded in this article and the 0 other(s) covering the same event.

Story

📰 XORTX FDA Submission Gout Treatment
Health · 1 article(s) covering the same event.

Compared with similar articles

Nothing to compare against. No article is close enough to this one for the pipeline to have linked or judged the pair.
How this article was measured signals, leaning charts, publisher record, byline, topics and claims

Signals How these are calculated →

Claims extracted
6
sentences that state something as happening or true
Uncertain
0%
0 of 6 hedged ("reportedly", "may", "according to")
Leaning
not political
takes no side on a contested political question
Publisher signals
64/100
Toronto Star's corrections and hedging, across everything collected from it. Not a measure of accuracy.
Outlets on this story
1
Health
Same framing elsewhere
1
articles that frame the event the way this one does
Analyzed 2026-09-19 · how these are computed

How this is being covered How these are calculated →

Article leaning vs. publisher reliability
Source leaning vs. consistency

Publisher

Toronto Star · 10694 article(s) · 27 correction(s) detected
Running correction rate · 27 correction(s)
2026-10-26
Correction
2026-10-24
Correction
2026-10-22
News Clarification for Oct. 22
2026-10-21
No. 6 Hoosiers try to for rare rebound at Michigan after turning the page on 22-game winning streak
2026-10-19
Driver’s License Suspensions for Court Debt Draw Scrutiny
2026-10-16
Amputations and cancer treatment delays: Lawmakers hear testimony on Mississippi prison healthcare
2026-10-16
UPDATE: Golconda Gold Releases Q3 2026 Production Update at Galaxy
2026-10-08
News Clarification for Oct. 8
2026-10-07
Correction
2026-10-05
Entertainment Correction for Oct. 5
2026-10-03
Tennessee's prisons chief is resigning after failed execution of Christa Pike
2026-09-28
Organizations call for Action to End the Deaths of Indigenous People in Custody
2026-09-27
Police memorial recognizes six officers killed in the line of duty in 2026
2026-09-27
UPDATE: WSP to host Power & Energy-focused investor event virtually only
2026-09-26
News Clarification for Sept. 27
2026-09-26
Former federal public servant seeks better pensions for injured workers
2026-09-25
News Corrections for Sept. 25
2026-09-25
She has not been charged. But the Project South allegations have branded her with a 'scarlet letter'
2026-09-24
Correction
2026-09-23
MULTIMEDIA UPDATE: Smith+Nephew launches the new EVOS™ PELVIC Plating System at the 2026 Orthopedic Trauma Association (OTA) Annual Meeting, expanding the EVOS Plating Platform for pelvic and acetabular fracture management
2026-09-22
Costa Rican man complained of lack of care for diabetes before his death in ICE custody, family says
2026-09-22
Judges' grilling of accused men leads to sex assault and dangerous driving cases being overturned
2026-09-20
Jura Energy Corporation Provides Clarification Regarding Media Reports Concerning Its Petroleum Rights in Pakistan
2026-09-19
New details emerge about Toronto's guns-for-hire and the 'crash-out mission" that sparked the Project South investigation
2026-09-17
UPDATE: Osisko Critical Minerals Corporation Announces C$100 Million Private Placement of Special Warrants
2026-09-17
Alabama set to execute man for pawn shop killings months after his nitrogen gas execution blocked
2026-09-04
Orca Corrects Q3 Quarterly Dividend Announcement

Who wrote this

No reporter is named on this article, beyond the feed's “GlobeNewswire, Inc.”.

Topics

CALGARY FDA XORLO™ XORTX XRX-OXY-102

Subjects

FDA ORG · 7× XORTX ORG · 3× Alberta GPE · 1× CALGARY GPE · 1× Company ORG · 1× GLOBE NEWSWIRE ORG · 1× XORTX Therapeutics Inc. ORG · 1× XRTX ORG · 1× the U.S. Food and Drug Administration ORG · 1×

Narrative

XORTX Therapeutics Inc. (“XORTX” or the “Company”) (NASDAQ: XRTX), a late-stage clinical pharmaceutical company focused on developing innovative therapies to treat gout and progressive kidney disease, outlines its anticipated Investigational New Drug application (“IND”) submission to the U.S. Food and Drug Administration (the “FDA”) for the XRx-026 gout program.
framing: assertive · carried by 1 article(s) · first seen 2026-09-19
🔮 The key steps the Company anticipates will be necessary to file a marketing application with the FDA include meetings with the agency, a two-part clinical study to characterize the pharmacokinetics and efficacy of the XORLO™ formulation of oxypurinol, and manufacture of a commercial supply of XORLO™ for the first year of marketing.
2026-09-19 · Toronto Star
XORTX Announces Planned FDA IND Submission for XRx-026 Gout Program Using XORLO™, Targeting USD$700M+ U.S. Gout Market Opportunity · assertive framing

Claims (6 extracted, 0 hedged)

XORTX Therapeutics Inc. (“XORTX” or the “Company”) (NASDAQ: XRTX), a late-stage clinical pharmaceutical company focused on developing innovative therapies to treat gout and progressive kidney disease, outlines its anticipated Investigational New Drug application (“IND”) submission to the U.S. Food and Drug Administration (the “FDA”) for the XRx-026 gout program. asserted
Inc. → focus → program
XORTX’s drug development plan is to seek FDA marketing approval for XRx-026 and provide patients with a new therapeutic option. asserted
plan → seek → option
The key steps the Company anticipates will be necessary to file a marketing application with the FDA include meetings with the agency, a two-part clinical study to characterize the pharmacokinetics and efficacy of the XORLO™ formulation of oxypurinol, and manufacture of a commercial supply of XORLO™ for the first year of marketing. asserted
Company → anticipate → marketing
Recent drug development team activities include preparation of a new IND for submission to the FDA in the fourth quarter of 2026. asserted
activities → include → 2026
The application describes the Company’s clinical development plan and its intention to file a New Drug Application (“NDA”) with the FDA following completion of the planned two-part XRX-OXY-102 clinical trial, which is being advanced based on positive and supportive prior clinical trial results and discussions with the FDA. asserted
which → describe → FDA
The focus of the XRX-OXY-102 clinical trial is to characterize key information needed by the FDA in its evaluation of a future NDA filing by XORTX for marketing approval. asserted
focus → characterize → approval
💬Give feedback
🕘History 🎫Support
Terms · Privacy · beta v2.0.0
Articles to 31 Oct 2026